Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691766 · ClinicalTrials.gov registry record · NA
Photobiomodulation Therapy in Persons With Multiple Sclerosis
A NA study, sponsored by Marquette University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03691766: Completed NA study, sponsored by Marquette University.
NCT03691766 is a NA study that has completed, run by Marquette University. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03691766, a NA study, has completed, sponsored by Marquette University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
Primary Outcome
Change in muscle fatigue or recovery after photobiomodulation therapy
Interventions
- OTHER Placebo
- OTHER Photobiomodulation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2019-09-23 |
| Phase | NA |
What the finished NCT03691766 record still lists
NCT03691766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03691766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03691766 about?
NCT03691766 is a clinical study titled "Photobiomodulation Therapy in Persons With Multiple Sclerosis". This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
What is the current status of trial NCT03691766?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2018-04-30. Estimated completion is 2019-09-23.
What interventions are being tested in trial NCT03691766?
The interventions under investigation include: Placebo (OTHER), Photobiomodulation Therapy (OTHER).
Who is sponsoring clinical trial NCT03691766?
This trial is sponsored by Marquette University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03691766's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI